Overall rank by patents
#40,845
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Imprimis Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, active 2016–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
6
Total patents granted
5
CPC technology areas
22.8
Avg claims per patent
-100%
5-year filing velocity
The verdict
Imprimis holds 6 US patents across 5 technology areas, rank #40,845 of 50,000 tracked assignees.
- #40,845
- of 50,000 US assignees by volume
- Top 73%
- by Innovation Score (28.3/100)
- 22.8
- avg claims per patent
- -100%
- filing velocity, last 5 yrs
Portfolio overview
Imprimis Pharmaceuticals, Inc. has been granted 6 US utility patents between 2016 and 2019, placing Imprimis Pharmaceuticals, Inc. at rank #40,845 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.8 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Imprimis Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Imprimis sits between IMO Industries Inc. (6 patents, rank #40,841) and Incom, Inc. (6 patents, rank #40,849) - the closest US assignees by grant volume. The composite Innovation Score of 28.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 6 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Imprimis Pharmaceuticals, Inc.'s 22.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Imprimis Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Imprimis's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- IMO Industries
IMO Industries Inc.
6 patents
- Impact Technology…
IMPACT TECHNOLOGY SYSTEMS AS
6 patents
- Imperial Blades
IMPERIAL BLADES
6 patents
- Implementation AP…
IMPLEMENTATION APPS LLC
6 patents
- IMS Solution
IMS SOLUTION, LLC
6 patents
- IMV
IMV CORPORATION
6 patents
- Inceptio Hongkong
INCEPTIO HONGKONG LIMITED
6 patents
- Incom
INCOM, INC.
6 patents
- Imprimis Pharmace… ◀
IMPRIMIS PHARMACEUTICALS, INC.
6 patents
What this shows Imprimis holds 6 patents at rank #40,845, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Imprimis
By rank, the assignees closest to #40,845 in granted patent volume.
- IMO Industries Inc. #40,841 · 6 patents
- Impact Technology Systems AS #40,842 · 6 patents
- Imperial Blades #40,843 · 6 patents
- Implementation APPS Llc #40,844 · 6 patents
- IMS Solution, Llc #40,846 · 6 patents
- IMV Corporation #40,847 · 6 patents
- Inceptio Hongkong Limited #40,848 · 6 patents
- Incom, Inc. #40,849 · 6 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Imprimis's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Imprimis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
28 Top 73% higher than 27% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2017 | 1 | 16.7% |
| 2018 | 1 | 16.7% |
| 2019 | 3 | 50.0% |
Which technologies does Imprimis Pharmaceuticals, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Imprimis Pharmaceuticals, Inc. hold?
Imprimis Pharmaceuticals, Inc. holds 6 US granted patents filed between 2016 and 2019, spanning 5 technology areas.
What is Imprimis Pharmaceuticals, Inc.'s Innovation Score?
Imprimis Pharmaceuticals, Inc. has an Innovation Score of 28.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Imprimis Pharmaceuticals, Inc. focus on?
Imprimis Pharmaceuticals, Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 6 patents. The company has filed patents in 5 CPC subclasses total.
Is Imprimis Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Imprimis Pharmaceuticals, Inc.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Imprimis Pharmaceuticals, Inc.'s patents?
Imprimis Pharmaceuticals, Inc.'s patents average 22.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Imprimis Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Imprimis's 6 grants land it in the top 73% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Imprimis ranks #40,845 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.